Advertisement
Advertisement
U.S. Markets closed
Advertisement
Advertisement
Advertisement
Advertisement

Todos Medical Ltd. (TOMDF)

Other OTC - Other OTC Delayed Price. Currency in USD
Add to watchlist
0.0178+0.0008 (+4.71%)
At close: 03:59PM EDT
Advertisement
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Neutralpattern detected
Previous Close0.0170
Open0.0169
Bid0.0000 x 0
Ask0.0000 x 0
Day's Range0.0150 - 0.0196
52 Week Range0.0100 - 0.1050
Volume4,841,936
Avg. Volume10,638,990
Market Cap16.276M
Beta (5Y Monthly)-1.19
PE Ratio (TTM)N/A
EPS (TTM)-0.1150
Earnings DateApr 21, 2021
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
  • GlobeNewswire

    Todos Medical Receives Two Notices of Allowance from USPTO for AI-Based TBIA Pan-Cancer Blood Diagnostics Platform

    New York, NY, and Tel Aviv, ISRAEL, Sept. 30, 2022 (GLOBE NEWSWIRE) -- via NewMediaWire -- Todos Medical, Ltd. (OTCQB: TOMDF), a comprehensive medical diagnostics and related solutions company, today announced that it has received two Notices of Allowance from the United States Patent & Trademark Office (USPTO) for patent applications covering the Company’s Total Biochemical Infrared Analysis (TBIA) Fourier Transformed Infrared (FTIR) pan-cancer blood diagnostics platform. The Notices of Allowan

  • GlobeNewswire

    Todos Medical Announces USPTO Trademark Notice of Allowance for 3CL Protease Biomarker Diagnostics TolloTest™

    New York, NY, and Tel Aviv, ISRAEL, Sept. 27, 2022 (GLOBE NEWSWIRE) -- via NewMediaWire -- Todos Medical, Ltd. (OTCQB: TOMDF), a comprehensive medical diagnostics and related solutions company, today announced that its majority-owned joint venture 3CL Pharma Ltd. received a Notice of Allowance issued by the USPTO for the Company’s proprietary SARS-CoV-2 3CL protease (Main protease, Mpro, Nsp5) diagnostic TolloTest™ that was developed to detect and quantify the presence of 3CL protease in human t

  • GlobeNewswire

    Todos Medical Enters Into $50M Contract to Supply Tollovid™ and CBD Products to Retail Distributor Company Nerd Hemp

    5500 Automated Retail Machines to be Rolled out in Q4/22 and Q1/23 $11.5M in Q4/22 Revenue Expected From This Agreement NEW YORK, NY and TEL AVIV, ISRAEL, Sept. 22, 2022 (GLOBE NEWSWIRE) -- via NewMediaWire – Todos Medical, Ltd. (OTCQB: TOMDF), a comprehensive medical diagnostics and related solutions company, today announced that it has entered into a distributor agreement to supply its proprietary 3CL protease inhibitor immune support dietary supplement Tollovid™ and botanical ‘0% THC’ CBD pro

Advertisement
Advertisement